Targeting protein degradation to treat advanced childhood tumors
Official title: PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors
Funded at Stanford University · NIH-11046406 · Data updated 2026-11-12
This study is working on new ways to treat kids with solid tumors, especially brain tumors, by finding and blocking certain proteins that help these cancers grow, using cutting-edge techniques to create better treatments that go beyond standard chemotherapy and radiation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $936,142 |
| NIH project number | 1OT2CA297508-01 |
| Project ID | NIH-11046406 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with advanced solid tumors, including brain tumors.
✕Less likely to help
Patients with non-solid tumors or those outside the specified age range may not benefit from this research.
What this research studies
This research focuses on developing innovative treatments for children with solid tumors, particularly brain tumors, by targeting specific proteins that drive these cancers. The approach utilizes advanced techniques like targeted protein degradation and CRISPR-Cas9 screening to identify and inhibit previously 'undruggable' oncoproteins. By collaborating with experts in various fields, the research aims to create effective therapies tailored to the unique biology of pediatric tumors, moving beyond traditional chemotherapy and radiotherapy methods.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for childhood cancers, potentially improving survival rates and quality of life for young patients.
How similar studies have gone: Other research has shown promise in targeting protein degradation for cancer treatment, indicating that this approach could lead to significant advancements in pediatric oncology.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Gray, Nathanael Schiander — Stanford University
- Study coordinator: Gray, Nathanael Schiander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.